Cochrane · systematic review · CD008562
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia
Martí‐Carvajal, AJ, Anand, V, Solà, I · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
11
No studies
9
Included studies
NR
No studies 9 · 32.1%Ungraded 8 · 28.6%Very low 11 · 39.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Human activated protein C versus heparin for DIC
Population: DIC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall mortality Human activated protein C vs heparin | no estimate extracted | 1 study · 132 participants | Ungraded |
Mortality from any cause (15‐day and 30‐day in‐hospital) Human activated protein C vs heparin | RR 0.51 [0.27, 0.97] | 1 study · 104 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Adverse events Human activated protein C vs heparin | RR 0.53 [0.05, 5.66] | 1 study · 107 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Bleeding Human activated protein C vs heparin | RR 0.06 [0, 1.09] | 1 study · 132 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Resolution of respiratory failure Human activated protein C vs heparin | no estimate extracted | NR | No studies |
Renal failure Human activated protein C vs heparin | no estimate extracted | NR | No studies |
Shock Human activated protein C vs heparin | no estimate extracted | NR | No studies |
Recombinant human soluble thrombomodulin compared with heparin for DIC
Population: DIC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall mortality Recombinant human soluble thrombomodulin vs heparin | no estimate extracted | 1 study · 234 participants | Ungraded |
Mortality from any cause (15‐day and 30‐day in‐hospital) Recombinant human soluble thrombomodulin vs heparin | RR 0.85 [0.54, 1.36] | 1 study · 227 participants | Very low Downgraded: imprecision, indirectness |
Adverse events Recombinant human soluble thrombomodulin vs heparin | RR 0.88 [0.35, 2.2] | 1 study · 231 participants | Very low Downgraded: imprecision, indirectness |
Bleeding Recombinant human soluble thrombomodulin vs heparin | no estimate extracted | 1 study · 234 participants | Very low Downgraded: indirectness |
Resolution of respiratory failure Recombinant human soluble thrombomodulin vs heparin | no estimate extracted | NR | No studies |
Renal failure Recombinant human soluble thrombomodulin vs heparin | no estimate extracted | NR | No studies |
Shock Recombinant human soluble thrombomodulin vs heparin | no estimate extracted | NR | No studies |
Tranexamic acid compared with placebo for DIC
Population: DIC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall mortality Tranexamic acid vs placebo | no estimate extracted | 1 study · 12 participants | Ungraded |
Mortality from any cause (15‐day and 30‐day in‐hospital) Tranexamic acid vs placebo | no estimate extracted | 1 study · 12 participants | Ungraded |
Adverse events Tranexamic acid vs placebo | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
Bleeding Tranexamic acid vs placebo | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
Resolution of respiratory failure Tranexamic acid vs placebo | no estimate extracted | 1 study · 12 participants | Ungraded |
Renal failure Tranexamic acid vs placebo | no estimate extracted | 1 study · 12 participants | Ungraded |
Shock Tranexamic acid vs placebo | no estimate extracted | 1 study · 12 participants | Ungraded |
Dermatan compared with heparin for DIC
Population: DIC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall mortality Dermatan vs heparin | no estimate extracted | 1 study · 10 participants | Ungraded |
Mortality from any cause (15‐day and 30‐day in‐hospital) Dermatan vs heparin | no estimate extracted | 1 study · 10 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Dermatan vs heparin | no estimate extracted | 1 study · 10 participants | Very low Downgraded: risk of bias, imprecision |
Bleeding Dermatan vs heparin | RR 0.5 [0.06, 3.91] | 1 study · 10 participants | Very low Downgraded: imprecision |
Resolution of respiratory failure ‐ not measured Dermatan vs heparin | no estimate extracted | NR | No studies |
Renal failure Dermatan vs heparin | no estimate extracted | NR | No studies |
Shock Dermatan vs heparin | no estimate extracted | NR | No studies |